CXCL16 and breast cancer: In a 4T1 breast cancer model, using antibodies to neutralize intratumoral CXCL16 not only liberated CXCR6+ effector-memory cells from the primary tumor but also led to their accumulation as CD103+CD69+ TRM cells in the lungs [15].